Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 7:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 44 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Mild to Moderate COVID-19 Clear all

Conditions: Mild-to-Moderate COVID-19
Interventions: KB109 + Self Supportive Care (SSC), Self Supportive Care (SSC) Alone; Other
Lead sponsor: Kaleido Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 12
States / cities: Cullman, Alabama • Los Angeles, California • Rancho Cucamonga, California + 7 more

Conditions: COVID-19
Interventions: nirmatrelvir, ritonavir; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 13
States / cities: Birmingham, Alabama • Cutler Bay, Florida • DeBary, Florida + 6 more

Conditions: Covid19
Interventions: Hyperbaric Oxygen Therapy; Other
Lead sponsor: Steward St. Elizabeth's Medical Center of Boston, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Taunton, Massachusetts

Conditions: Coronavirus Disease 2019
Interventions: Placebo, Leronlimab (700mg); Drug
Lead sponsor: CytoDyn, Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 12
States / cities: Los Angeles, California • Palm Springs, California • Rancho Mirage, California + 9 more

Conditions: COVID, Covid-19, Coronavirus, Coronavirus Infection, Severe Acute Respiratory Syndrome, Severe Acute Respiratory Syndrome Coronavirus 2, Sars-CoV2, Ards, Acute Respiratory Distress Syndrome
Interventions: APL-9, Vehicle Control; Drug · Other
Lead sponsor: Apellis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 16
States / cities: Fresno, California • San Francisco, California • Jacksonville Beach, Florida + 12 more

Conditions: COVID-19, Coronavirus, Coronavirus Infection
Interventions: INOpulse, Placebo; Combination Product
Lead sponsor: Bellerophon Pulse Technologies; Industry
Eligibility: 18 Years and older
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 17
States / cities: Phoenix, Arizona • San Diego, California • Miami, Florida + 8 more

Conditions: COVID-19, Coronavirus, SARS-CoV2 Infection
Interventions: Rayaldee, Placebo; Drug
Lead sponsor: OPKO Health, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 10
States / cities: San Francisco, California • Miami, Florida • Evanston, Illinois + 6 more

Conditions: Mild-to-moderate COVID-19
Interventions: KB109 + Self Supportive Care (SSC), Self Supportive Care (SSC) Alone; Other
Lead sponsor: Kaleido Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 16
States / cities: Hot Springs, Arkansas • Riverside, California • San Diego, California + 12 more

Conditions: Covid-19
Interventions: CPI-006 2 mg/kg + SOC, CPI-006 1 mg/kg + SOC, Placebo + SOC; Drug
Lead sponsor: Corvus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 13
States / cities: Chula Vista, California • El Centro, California • La Mesa, California + 10 more

Conditions: COVID-19
Interventions: Nitazoxanide, Placebo, Vitamin Super B-Complex; Drug · Dietary Supplement
Lead sponsor: Romark Laboratories L.C.; Industry
Eligibility: 12 Years to 120 Years
Enrollment: 935 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Fort Lauderdale, Florida • The Bronx, New York

Conditions: COVID-19
Interventions: Bamlanivimab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 12 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Covid19
Interventions: Camostat Mesilate, Placebo, Standard of Care Treatment; Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Stanford, California

Conditions: COVID-19
Interventions: albuterol sulfate (MDI), albuterol sulfate (nebulizer); Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: COVID-19
Interventions: Bamlanivimab, Etesevimab, Placebo, VIR-7831, Bebtelovimab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 12 Years and older
Enrollment: 1,755 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 127
States / cities: Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 103 more

Conditions: COVID-19 (Coronavirus Disease 2019)
Interventions: nirmatrelvir-ritonavir; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 131,005 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Coronavirus Infections, Pneumonia, Viral, Acute Respiratory Distress Syndrome
Interventions: Nitric Oxide; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Shreveport, Louisiana • Boston, Massachusetts

Conditions: Covid19
Interventions: Favipiravir, Placebo; Drug
Lead sponsor: Appili Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 25
States / cities: Pelham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 14 more

Conditions: Covid-19
Interventions: Antroquinonol, Placebo; Drug · Other
Lead sponsor: Golden Biotechnology Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 5
States / cities: Michigan City, Indiana • Wichita, Kansas • Rockville, Maryland + 2 more

Conditions: Covid19
Interventions: BAMLANIVIMAB, CASIRIVIMAB, IMDEVIMAB; Biological
Lead sponsor: Sohail Rao; Other
Eligibility: 12 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Edinburg, Texas • Rio Grande City, Texas

Conditions: Efficacy and Safety
Interventions: Proxalutamide (GT0918), Placebo; Drug
Lead sponsor: Suzhou Kintor Pharmaceutical Inc,; Industry
Eligibility: 18 Years and older
Enrollment: 733 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 8
States / cities: Phoenix, Arizona • Long Beach, California • Sandy Springs, Georgia + 5 more

Conditions: SARS-CoV2 Infection, COVID-19
Interventions: IMM-BCP-01, Placebo; Drug
Lead sponsor: Immunome, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Long Beach, California • Miami Lakes, Florida • New York, New York

Conditions: COVID, Sars-CoV2, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere, Oxidative Stress
Interventions: N-acetylcysteine; Drug
Lead sponsor: Cambridge Health Alliance; Other
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 4
States / cities: Cambridge, Massachusetts • Everett, Massachusetts • Somerville, Massachusetts

Conditions: COVID19
Interventions: RD-X19, Sham; Device
Lead sponsor: EmitBio Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 9
States / cities: Clearwater, Florida • Miami, Florida • Kalamazoo, Michigan + 6 more

Conditions: COVID-19
Interventions: EDP-235, Placebo; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 22
States / cities: Lomita, California • Los Angeles, California • Aventura, Florida + 10 more

Search by objective public record fields.

A Clinical Study to Assess the Physiologic Effects of KB109 in Patients With COVID-19 on Gut Microbiota Structure and Function

A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19

Use of Hyperbaric Oxygen Therapy to Treat COVID-19 Patients With Respiratory Distress

Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19

A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19

A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19

Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19

A Clinical Study to Assess the Natural History of COVID-19 and Effects of KB109 and Supportive Self-care in Outpatients With Mild-to-moderate COVID-19

CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients

Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19

A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients

Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19

A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness

A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe

Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19

The Prevent Severe COVID-19 (PRESECO) Study

Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients

Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting

Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness

IMM-BCP-01 in Mild to Moderate COVID-19

Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease

Evaluation of the RD-X19 Treatment Device in Individuals With Mild to Moderate COVID-19

A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19